Literature DB >> 10918163

Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.

A Kamimura1, M Kamachi, J Nishihira, S Ogura, H Isobe, H Dosaka-Akita, A Ogata, M Shindoh, T Ohbuchi, Y Kawakami.   

Abstract

BACKGROUND: Macrophage migration inhibitory factor (MIF) is known to be a proinflammatory cytokine and glucocorticoid-induced immunomodulator as well as a regulator of tumor growth. Although positive and negative effects of MIF on tumor cell growth have been reported, to the authors' knowledge the precise role of MIF in tumorigenesis remains unclear. In the current study the authors assessed expression of MIF protein and mRNA in lung adenocarcinomas with regard to patient prognosis.
METHODS: Immunohistochemical analysis was performed on tissue specimens surgically obtained from 74 patients with primary lung adenocarcinoma (American Joint Committee on Cancer pathologic Stages I, II, and IIIa). In addition, expression of MIF mRNA in the cancerous tissue was investigated using in situ hybridization. Patient prognosis was evaluated with regard to MIF expression levels and its distribution was analyzed with the Kaplan-Meier method.
RESULTS: MIF mRNA and MIF protein were observed in the bronchial epithelium, alveolar epithelium, vascular smooth muscle, and alveolar macrophages in the normal lung tissue. In tumor tissue from lung adenocarcinoma specimens, both MIF mRNA and protein were observed at much higher levels than in the normal alveolar epithelium. MIF protein was observed diffusely in the cytoplasm of tumor cells in all tumor specimens examined. MIF protein also was observed in the nuclei of tumor cells from 59 patients (79.7%), whereas it was not observed in the nuclei of tumor cells from 15 patients (20.3%). The patients without nuclear MIF expression had a worse prognosis compared with those patients with MIF expression in the nuclei (P = 0.04).
CONCLUSIONS: The results of the current study suggest that intracellular MIF distribution predicts patient prognosis in individuals with adenocarcinoma of the lung. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918163

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  54 in total

1.  Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer.

Authors:  Majid Nabizadeh Marvast; Hamid Reza Sima; Kamran Ghaffarzadehgan; Ali Taghizadeh Kermani; Nona Norouzi
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  Oxygen regulation of macrophage migration inhibitory factor in human placenta.

Authors:  Francesca Ietta; Yuanhong Wu; Roberta Romagnoli; Nima Soleymanlou; Barbara Orsini; Stacy Zamudio; Luana Paulesu; Isabella Caniggia
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08-29       Impact factor: 4.310

3.  Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.

Authors:  Chia-Tung Shun; Jaw-Town Lin; Shih-Pei Huang; Min-Tsan Lin; Ming-Shiang Wu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.

Authors:  William L Bigbee; Vanathi Gopalakrishnan; Joel L Weissfeld; David O Wilson; Sanja Dacic; Anna E Lokshin; Jill M Siegfried
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

5.  Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Authors:  Naotake Funamizu; Chaoxin Hu; Curtis Lacy; Aaron Schetter; Geng Zhang; Peijun He; Jochen Gaedcke; Michael B Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Jeffrey Subleski; Tim Chan; Jonathan M Weiss; Timothy C Back; Katsuhiko Yanaga; Nader Hanna; H Richard Alexander; Anirban Maitra; S Perwez Hussain
Journal:  Int J Cancer       Date:  2013-02-15       Impact factor: 7.396

6.  Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets.

Authors:  Nadège Kindt; Fabrice Journe; Guy Laurent; Sven Saussez
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

7.  Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma.

Authors:  Ilkyu Han; Mi Ra Lee; Kwang Woo Nam; Joo Han Oh; Kyung Chul Moon; Han-Soo Kim
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

Review 8.  Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.

Authors:  Beatriz E Rendon; Sharon S Willer; Wayne Zundel; Robert A Mitchell
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

9.  Intratumoral expression of macrophage migration inhibitory factor is correlated with serum C-reactive protein and interleukin-6 in patients with non-small cell lung cancer.

Authors:  Motoharu Hamatake; Ichiro Yoshino; Makiko Tomiyasu; Naoko Miura; Hiroshi Okazaki; Taro Ohba; Tomohiro Takenaka; Yoshihiko Maehara
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

10.  The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.

Authors:  Hakan Camlica; Derya Duranyildiz; Hilal Oguz; Ethem Nezih Oral; Vildan Yasasever
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.